Reality Check on Anemia — Chronic Kidney Disease
Market access for anemia treatments due to chronic kidney disease reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 39% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In January 2020, the FDA approved Pharmacosmos Therapeutics Inc.’s Monoferric (ferric derisomaltose) injection 100 mg/mL to treat iron deficiency anemia in adult patients who have an intolerance to oral iron, have had an unsatisfactory response to oral iron or have nonhemodialysis-dependent chronic kidney disease
- Key Findings: New-to-market products will have to compete with well-established erythropoiesis-stimulating agents and a biosimilar, as well as an IV iron replacement product for people not on dialysis. Products with improved side-effect profiles compared with ESAs will have an advantage
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.